Diagonal Bio

During the exercise period from and including September 12, 2024, up to and including September 26, 2024, holders of warrants of series TO 1 have had the right to subscribe for one (1) new share in Diagonal for each warrant of series TO 1 at a price of SEK 0,05 per share. A total of 77.794 warrants of series TO 1 have been exercised for subscription of 77.794 shares, corresponding to a subscription of SEK 3.889,70. The Board of Directors of Diagonal will decide on the allocation during the day. The exercise entails a dilution of 0,02 percent. Conversion from interim shares to ordinary shares is expected to take place around 11 October 2024 and ordinary shares are expected to be visible on each subscriber's depository account approximately two banking days thereafter.

After registration, the number of shares in the Company will amount to 400.714.213 shares and the share capital will amount to SEK 3.998.354,13.

For more information about the TO 1, please contact:

Sedermera Corporate Finance AB

Tel: +46 (0)40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

For more information, please contact:

Karin Wehlin, VD

Phone: +46 (0)70 305 24 88

E-mail: kw@diagonalbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

E-mail: ca@skmg.se

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.